Peptide Therapeutics Market by Technology, Drug Class, Route of Administration, Application, End User, Manufacturing Type - Global Forecast 2025-2030- Product Image

Sale

Peptide Therapeutics Market by Technology, Drug Class, Route of Administration, Application, End User, Manufacturing Type - Global Forecast 2025-2030

Report
196 Pages
October 2024
Region: Global
360iResearch™
ID: 4968565

UP TO €665EUR$697USD£557GBP OFF until Dec 31^st 2024

The Peptide Therapeutics Market grew from USD 33.06 billion in 2023 to USD 35.76 billion in 2024. It is expected to continue growing at a CAGR of 8.35%, reaching USD 57.97 billion by 2030.

Peptide therapeutics involves the use of peptides - short chains of amino acids - as treatments in various medical fields due to their specificity, efficacy, and safety profiles. The necessity for peptide therapeutics has burgeoned due to rising chronic disease incidences and an increasing shift towards biologic drugs, offering targeted treatment with fewer side effects compared to small molecule drugs. These therapeutics have applications across oncology, metabolic disorders, infectious diseases, and hormonal deficiencies. End-use scopes include pharmaceuticals, biotechnology companies, and research institutes. Market insights reveal that factors such as increased R&D investments, innovations in drug delivery systems, and advances in peptide synthesis technologies drive market growth. Additionally, the growing interest in personalized medicine and orphan drugs offers significant opportunities. Companies can benefit from leveraging advancements in synthetic biology and nanotechnology to develop next-generation peptide therapeutics. However, market growth is limited by challenges including high production costs, stability issues, regulatory hurdles, and the complexity of peptide manufacturing processes, which can hinder scalability and commercial viability. Best areas for innovation include improving oral bioavailability of peptide drugs and developing novel delivery systems like nanoparticles and transdermal patches, which could enhance market penetration. Exploring synthetic methodologies to reduce manufacturing costs and harnessing artificial intelligence to design tailor-made peptides can be transformative. The market is competitive but fragmented, with an emerging trend towards partnerships and collaborations for better market positioning. Integrating comprehensive market analytics, leveraging existing collaborations, and focusing on specific therapeutic areas such as cancer or autoimmune diseases can aid in tapping into unmet medical needs. By focusing on these strategic innovations and overcoming persistent challenges, companies can effectively navigate through this evolving landscape to ensure sustained growth and competitive advantage.

Understanding Market Dynamics in the Peptide Therapeutics Market

The Peptide Therapeutics Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Prevalence of chronic diseases and need for effective therapeutic options
- Exponential use of peptides in aesthetic dermatology
Market Restraints
- Adverse recalls of peptide therapeutics
Market Opportunities
- Ongoing R&D activities for new peptide development worldwide
- Shift toward personalized medicine and identification of peptide biomarkers
Market Challenges
- Production complexity and bioavailability issues of peptide therapeutics

Exploring Porter’s Five Forces for the Peptide Therapeutics Market

Porter’s Five Forces framework further strengthens the insights of the Peptide Therapeutics Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Peptide Therapeutics Market

External macro-environmental factors deeply influence the performance of the Peptide Therapeutics Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Peptide Therapeutics Market

The Peptide Therapeutics Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Peptide Therapeutics Market

The Peptide Therapeutics Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Key Company Profiles

The report delves into recent significant developments in the Peptide Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AmbioPharm, Inc., Amgen Inc., Amide Technologies, Inc., AstraZeneca PLC, Bachem Holding AG, Biosynth Ltd., Bristol Myers Squibb Company, Cidara Therapeutics, Inc., Corden Pharma International GmbH, Cybrexa, Inc., Eccogene, Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Ipsen Group, IRBM S.p.A., Ironwood Pharmaceuticals, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co., Ltd., Peptidream Co., Ltd., Perpetual Medicines Corporation, Pfizer Inc., Piramal Pharma Limited, PolyPeptide Group AG, RELIEF THERAPEUTICS Holding SA, Sanofi S.A., Sanyou Biopharmaceuticals Co., Ltd., Shanghai Full-Life Technologies Co, Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, WuXi AppTec Co., Ltd., and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Peptide Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Technology
- Hybrid Phase
- Liquid Phase
- Solid Phase
Drug Class
- Adrenocorticotropic Hormone
- Calcitonin
- Insulin
- Leuprorelin
- Octreotide
- Vasopressin
Route of Administration
- Intravenous Administration
- Nasal & Pulmonary Administration
- Oral Administration
- Transdermal Administration
Application
- Cardiovascular Disorders
- Gastrointestinal Disorders
- Infectious Disorders
- Neurological Disorders
- Oncology
End User
- Hospitals & Clinics
- Long-term Care Facilities
- Research Laboratories
Manufacturing Type
- Contract Manufacturing Organization
- In-house

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - Indiana
    - Maryland
    - Massachusetts
    - Minnesota
    - New Jersey
    - New York
    - North Carolina
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of chronic diseases and need for effective therapeutic options
5.1.1.2. Exponential use of peptides in aesthetic dermatology
5.1.2. Restraints
5.1.2.1. Adverse recalls of peptide therapeutics
5.1.3. Opportunities
5.1.3.1. Ongoing R&D activities for new peptide development worldwide
5.1.3.2. Shift toward personalized medicine and identification of peptide biomarkers
5.1.4. Challenges
5.1.4.1. Production complexity and bioavailability issues of peptide therapeutics
5.2. Market Segmentation Analysis
5.2.1. Technology: Rising utilization of solid phase approach for synthesis of complex peptides
5.2.2. Drug Class: Increasing need for insulin to regulate glucose metabolism for type 1 and type 2 diabetes
5.2.3. Route of Administration: Rising adoption of intravenous administration due to peptide therapeutics immediacy and effectiveness in acute hospital care settings
5.2.4. Application: Widening use of peptide therapeutics in cardiovascular disorders to simulate the action of endogenous peptides involved in blood pressure regulation
5.2.5. End User: Expanding the use of peptide therapeutics in hospitals and clinics to address and manage patient conditions
5.2.6. Manufacturing Type: Increasing adoption of CMOs owing to the need for specialized manufacturing capabilities and the ability to scale production rapidly
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Peptide Therapeutics Market, by Technology

6.1. Introduction
6.2. Hybrid Phase
6.3. Liquid Phase
6.4. Solid Phase

7. Peptide Therapeutics Market, by Drug Class

7.1. Introduction
7.2. Adrenocorticotropic Hormone
7.3. Calcitonin
7.4. Insulin
7.5. Leuprorelin
7.6. Octreotide
7.7. Vasopressin

8. Peptide Therapeutics Market, by Route of Administration

8.1. Introduction
8.2. Intravenous Administration
8.3. Nasal & Pulmonary Administration
8.4. Oral Administration
8.5. Transdermal Administration

9. Peptide Therapeutics Market, by Application

9.1. Introduction
9.2. Cardiovascular Disorders
9.3. Gastrointestinal Disorders
9.4. Infectious Disorders
9.5. Neurological Disorders
9.6. Oncology

10. Peptide Therapeutics Market, by End User

10.1. Introduction
10.2. Hospitals & Clinics
10.3. Long-term Care Facilities
10.4. Research Laboratories

11. Peptide Therapeutics Market, by Manufacturing Type

11.1. Introduction
11.2. Contract Manufacturing Organization
11.3. In-house

12. Americas Peptide Therapeutics Market

12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States

13. Asia-Pacific Peptide Therapeutics Market

13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam

14. Europe, Middle East & Africa Peptide Therapeutics Market

14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom

15. Competitive Landscape

15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
15.3.1. Novartis and PeptiDream collaborated to develop advanced oncology therapies with a USD 180 million deal a USD 2.8 billion deal
15.3.2. Expansion of GMP Capacities at CordenPharma Frankfurt: Elevating Early-Phase Peptide API Manufacturing
15.3.3. Revolutionizing Peptide Therapeutics: Orbis Medicines Innovates for Oral Drug Delivery
15.3.4. Copenhagen's Orbis Medicines launched peptide therapeutics with advanced macrocyclic technology for enhanced oral bioavailability
15.3.5. Expanding Facilities in Peptide Therapeutic Production: WuXi AppTec's Strategic Growth
15.3.6. Glenmark Pharmaceuticals Announces Biosimilar Liraglutide Launch in India to Revolutionize Anti-Diabetic Treatment
15.3.7. Amide Technologies' Novel Manufacturing Platform and Strategic Capital Advancement
15.3.8. Strategic Acquisition Elevates Pharmathen's Position in the Peptide Therapeutics Market
15.3.9. Biosynth Solidifies Market Position with Strategic Acquisition of Pepceuticals
15.3.10. Strategic Collaboration between PeptiDream and Genentech to Advance Peptide-Radioisotope Therapeutics
15.3.11. Merck and IRBM Forge Forward in Peptide Therapeutics: A Partnership to Expand and Innovate in Biopharmaceuticals
15.3.12. Fujitsu Launches Pioneering Bio-Drug Design Accelerator Focused on Advancing Peptide Therapeutics in Cancer and CNS Regeneration
15.3.13. Comprehensive Support for Peptide Therapeutics Development from Conception to Manufacturing for Introducing SynCrest's CRDMO Service

List of Figures

FIGURE 1. PEPTIDE THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. PEPTIDE THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2023 VS 2030 (%)
FIGURE 17. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 21. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. PEPTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 27. PEPTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. PEPTIDE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. PEPTIDE THERAPEUTICS MARKET DYNAMICS
TABLE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYBRID PHASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID PHASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SOLID PHASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LEUPRORELIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY VASOPRESSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NASAL & PULMONARY ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 55. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 56. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 57. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 61. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 62. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 65. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 80. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 87. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 93. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 94. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 105. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 106. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 107. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 141. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 142. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 160. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 161. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 164. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 166. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 167. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 168. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 172. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 173. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 178. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 179. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 180. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 182. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 184. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 186. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 194. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 196. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 197. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 198. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 214. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 215. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 216. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 218. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 220. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 221. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 222. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 224. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 226. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 227. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 228. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 248. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 250. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 251. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 252. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 268. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 269. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 270. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 272. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 284. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 286. PEPTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 287. PEPTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Peptide Therapeutics market, which are profiled in this report, include:

AbbVie Inc.
AmbioPharm, Inc.
Amgen Inc.
Amide Technologies, Inc.
AstraZeneca PLC
Bachem Holding AG
Biosynth Ltd.
Bristol Myers Squibb Company
Cidara Therapeutics, Inc.
Corden Pharma International GmbH
Cybrexa, Inc.
Eccogene
Eli Lilly and Company
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline PLC
Ipsen Group
IRBM S.p.A.
Ironwood Pharmaceuticals, Inc.
Merck KGaA
Novartis AG
Novo Nordisk A/S
Otsuka Pharmaceutical Co., Ltd.
Peptidream Co., Ltd.
Perpetual Medicines Corporation
Pfizer Inc.
Piramal Pharma Limited
PolyPeptide Group AG
RELIEF THERAPEUTICS Holding SA
Sanofi S.A.
Sanyou Biopharmaceuticals Co., Ltd.
Shanghai Full-Life Technologies Co, Ltd.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Limited
WuXi AppTec Co., Ltd.
Zealand Pharma A/S

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	196
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 35.76 Billion
Forecasted Market Value ( USD ) by 2030	$ 57.97 Billion
Compound Annual Growth Rate	8.3%
Regions Covered	Global
No. of Companies Mentioned	37

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3382EUR$3,545USD£2,833GBP €3758EUR$3,939USD£3,148GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€5984EUR$6,272USD£5,013GBP €6649EUR$6,969USD£5,570GBP

Understanding Market Dynamics in the Peptide Therapeutics Market

Exploring Porter’s Five Forces for the Peptide Therapeutics Market

Applying PESTLE Analysis to the Peptide Therapeutics Market

Analyzing Market Share in the Peptide Therapeutics Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Peptide Therapeutics Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Peptide Therapeutics Market Size, Share & Trends Analysis Report by Application (Cancer, Metabolic Disorders), Type (Generic, Innovative), Type of Manufacturer, Route of Administration, Synthesis Technology, Region, and Segment Forecasts, 2024-2030

Peptide Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030

Peptide Therapeutics Global Market Report 2024

Peptide Therapeutics Market Report by Type, Type of Manufacturer, Synthesis Technology, Routes of Administration, Application, and Region 2024-2032

Peptide Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030